ClinicalTrials.gg
RecruitingNCT06351592GOALSUpdated Sep 11, 2026

First in Human (FIH) Study of ALN-SOD in Adult Participants With Amyotrophic Lateral Sclerosis Associated With Mutation in the SOD1 Gene (SOD1-ALS)

A Phase 1/2 interventional study of ALN-SOD and Diluent in Amyotrophic Lateral Sclerosis (ALS) and Mutation in the Superoxide Dismutase-1 (SOD1) Gene, sponsored by Regeneron Pharmaceuticals. Recruiting at 22 sites in 9 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-09-11.

Sponsored by Regeneron Pharmaceuticals · Phase 1/2, Interventional, and Treatment

How we know

From the registry’s dates

  • Started Aug 2024; still recruiting 2 years 2 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1/2
Study type
Interventional
Enrollment
54
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 82 studies in Amyotrophic Lateral Sclerosis with a site in Canada — 15 open to participants now, 25 under way, 5 of them phase 3. Amyotrophic Lateral Sclerosis · Canada.

Planned enrollment
46th of 72
54 · median 75
Started
2024
with 8 others
Phase 1/2
4 of 82
2 open now
Primary completion
2032-03
later than 24 of 24 live
Registered
69th of 82
by date

Among the 82 studies in Amyotrophic Lateral Sclerosis with a site in Canada, this one is the 46th largest by planned enrollment of the 72 interventional ones that give a count, is one of 9 that started in 2024, is one of 4 in phase 1/2, reaches primary completion later than 24 of the 24 other live ones, and was the 69th registered.

Amyotrophic Lateral Sclerosis

981 studies on the registry are indexed under Amyotrophic Lateral Sclerosis; 280 are open to participants now.

Browse Amyotrophic Lateral Sclerosis studies →

Open to participants now

15 of the 82 studies in Amyotrophic Lateral Sclerosis with a site in Canada are open now. Recruiting first, the newest first:

9 more — sign in →

All 15 open studies →

A study can be open while its sites in Canada have not opened yet or have stopped. Only those recruiting at a site in Canada →

Who these studies take

Of the 194 Amyotrophic Lateral Sclerosis studies recruiting now, 119 (61%) set no upper age limit and 23 (12%) stop at 75 or younger; 15 take children under 18; 56 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 82 studies in Amyotrophic Lateral Sclerosis with a site in Canada, or all of them as a file.
02

Study summary

This study is researching an experimental drug called ALN-SOD (called "study drug"). This study is focused on people with Amyotrophic Lateral Sclerosis (ALS) caused by a change in a gene called the Superoxide Dismutase-1 (SOD1) gene. This type of ALS is known as "SOD1-ALS". This is the first time that ALN-SOD will be given to people.

The aim of the study is to see how safe and tolerable the study drug is.

The study is looking at several other research questions, including:

  • The effect the study drug has on specific biomarkers, which are substances in the blood or in the fluid that surrounds the brain and spinal cord, known as Cerebrospinal Fluid (CSF)
  • How much study drug is in the blood and in the CSF, at different times
  • Whether the body makes antibodies against the study drug (which could make the drug less effective or could lead to side effects)
  • What effects the study drug has on ALS symptoms
03

Conditions studied

  • Amyotrophic Lateral Sclerosis (ALS)
  • Mutation in the Superoxide Dismutase-1 (SOD1) Gene

Keywords

  • Symptomatic
  • Known pathogenic mutation
  • Predicted pathogenic mutation
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Eligibility criteria

Key Inclusion Criteria:

  1. Weakness attributable to ALS and a SOD1 variant that has been previously described as associated with ALS or is considered likely to cause ALS, as defined in the protocol
  2. Slow Vital Capacity (SVC) ≥50% predicted value based on age, gender and height, measured in upright position
  3. (BMI) ≤35 kg/m2 at time of screening
  4. If participants are taking riluzole or edaravone, they must be on a stable dose for at least 4 weeks prior to initial dosing visit and are expected to remain at that dose until the end of the study
  5. count >50,000/microliter
  6. Has normal blood pressure readings, as defined in the protocol

Key Exclusion Criteria:

  1. Concurrent participation in another interventional clinical trial
  2. Has had a tracheostomy
  3. Has dementia, as assessed by the investigator
  4. Has uncontrolled psychiatric disease, including psychosis, active or recent suicidal ideation, untreated major depression, in the past 30 days
  5. Has a medical history of brain or spinal disease/injury that would interfere with the Lumbar Puncture (LP) process, CSF circulation or safety assessment, as defined in the protocol
  6. Presence of an implanted shunt for the drainage of CSF or an implanted Central Nervous System (CNS) catheter
  7. Presents any concern to the study investigator that might confound the results of the study or poses an additional risk to the participant by their participation in the study
  8. Was hospitalized (ie, >24 hours) for any reason other than ALS within 30 days of screening
  9. Has received treatment with tofersen within 6 months prior to screening

NOTE: Other protocol defined inclusion / exclusion criteria apply

Terms in these criteria, in plain language(2)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

Platelets

Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.

05

Study design

Phase
Phase 1 / Phase 2
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Sequential assignment
Masking
None (open label)
Enrollment
54 participants (estimated)

Study arms

  • Experimental
    Cohort 1 - Dose Level 1

    Placebo during 4-Week double-blind treatment period

    Drug: ALN-SOD · Other: Diluent · Drug: Placebo (PB)

  • Experimental
    Cohort 2 - Dose Level 2

    Placebo during 4-Week double-blind treatment period

    Drug: ALN-SOD · Other: Diluent · Drug: Placebo (PB)

  • Experimental
    Cohort 3 - Dose Level 3

    Placebo during 4-Week double-blind treatment period

    Drug: ALN-SOD · Other: Diluent · Drug: Placebo (PB)

  • Experimental
    Cohort 4 - Dose Level 4

    Placebo during 4-Week double-blind treatment period

    Drug: ALN-SOD · Other: Diluent · Drug: Placebo (PB)

  • Experimental
    Cohort 5 (Optional) - ≤ Dose Level 5

    Placebo during 4-Week double-blind treatment period

    Drug: ALN-SOD · Other: Diluent · Drug: Placebo (PB)

  • Experimental
    Selected Dose Expansion Cohort(s)

    Open Label Treatment (OLT) at selected dose levels. EU Participants can only be included in the Dose Expansion portion of study (Phase 2), not in Dose Escalation (Phase 1)

    Drug: ALN-SOD

Interventions

  • DrugALN-SOD

    Administered per the protocol

  • OtherDiluent

    Administered per the protocol

  • DrugPlacebo (PB)

    Administered per the protocol

06

What researchers measure

Primary outcomes

  1. Incidence of Treatment-Emergent Adverse Event (TEAEs) in participants treated with ALN-SOD

    Time frame: At week 4 and through week 228

  2. Severity of TEAEs in participants treated with ALN-SOD

    Time frame: At week 4 and through week 228

Secondary outcomes

  1. Concentration of Neurofilament Light chain (NfL) in plasma over time

    Time frame: Up to approximately week 228

  2. Change in concentration of NfL in plasma over time

    Time frame: Up to approximately week 228

  3. Concentration of SOD1 protein in Cerebrospinal Fluid (CSF) over time

    Time frame: Up to approximately week 228

  4. Change in concentration of SOD1 protein in CSF over time

    Time frame: Up to approximately week 228

  5. Concentration of NfL in CSF over time

    Time frame: Up to approximately week 228

  6. Change in concentration of NfL in CSF over time

    Time frame: Up to approximately week 228

  7. Change in Amyotrophic Lateral Sclerosis Functional Rating Scale-Revised (ALSFRS-R) over time

    Time frame: Up to approximately week 228

  8. Concentration of ALN-SOD in plasma over time

    Time frame: Up to approximately week 228

  9. Concentration of ALN-SOD in CSF over time

    Time frame: Up to approximately week 228

  10. Incidence of Anti-Drug Antibodies (ADAs) to ALN-SOD in serum over time

    Time frame: Up to approximately week 228

  11. Titer of ADAs to ALN-SOD in serum over time

    Time frame: Up to approximately week 228

07

Study locations

22 of 22 sites recruiting
08

References and documents

Individual participant data

Plan to share: Yes — All Individual Patient Data (IPD) that underlie publicly available results will be considered for sharing.

Supporting information: Study protocol, Statistical analysis plan, Informed consent form, Clinical study report, Analytic code

Time frame: When Regeneron has: received marketing authorization from major health authorities (e.g., FDA, European Medicines Agency (EMA), Pharmaceuticals and Medical Devices Agency (PMDA), etc.) for the product and indication or has globally discontinued development of the product for all indications on or after April 2020 and has no plans for future development made the study results publicly available (e.g., scientific publication, scientific conference, clinical trial registry) the legal authority to share the data, and ensured the ability to protect participant privacy

Access criteria: Qualified researchers can submit a proposal for access to individual patient or aggregate level data from a Regeneron-sponsored clinical trial through Vivli. Regeneron's Independent Research Request Evaluation Criteria can be found at: https://www.regeneron.com/sites/default/files/Regeneron-External-Data-Sharing-Policy-and-Independent-Research-Request-Evaluation-Criteria.pdf

Data sharing details ↗ · vivli.org

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Aug 2024 (actual). Primary completion is estimated for Mar 2032, 90 months after the start.

Of 36 phase 1/2 interventional studies under Amyotrophic Lateral Sclerosis, half reached primary completion within 33 months of starting (the median), counting those still running; a quarter within 25 and three quarters within 57. This study's planned 90 months is above that.

How these figures are worked out, and which studies are left out of them.

Registered
Apr 2, 2024
First posted
Apr 8, 2024
StartActual
Aug 28, 2024
Primary completionEst.
Mar 21, 2032
CompletionEst.
Mar 21, 2032
Last update
Sep 11, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Sep 11, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT06351592
Responsible party
Sponsor
First posted
Apr 8, 2024
Start date
Aug 28, 2024
Primary completion
Mar 21, 2032 (estimated)
Completion
Mar 21, 2032 (estimated)
Last update
Sep 11, 2026

Study contacts

Clinical Trials Administrator
Contact
clinicaltrials@regeneron.com
844-734-6643
Clinical Trial Management
study director · Regeneron Pharmaceuticals

Oversight

Data monitoring committee
No
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion